Free Trial
→ This little-known fund tracks gold and pays out weekly (From Investors Alley) (Ad)tc pixel
NASDAQ:NKTX

Nkarta Q3 2026 Earnings Date & Estimates

Nkarta logo
$1.54 +0.03 (+1.64%)
As of 02:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Nkarta is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for November 9, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Nkarta in Q3 2026

Nkarta is expected to post earnings of -$0.40 per share. In the same quarter a year earlier Nkarta reported -$0.29 per share. Nkarta last reported on August 10, 2026, posting -$0.54 per share and missing the -$0.3603 consensus estimate. Nkarta has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.40
Prior-Year EPS
-$0.29

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.54 (Missed by -$0.1797)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Nkarta Q3 2026 Earnings FAQ

Nkarta (NASDAQ:NKTX) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Nkarta's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Nkarta to post earnings of -$0.40 per share for Q3 2026.

Nkarta Earnings Headlines

H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)
September 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NKTX/pressreleases/4750103/hc-wainwright-reaffirms-their-buy-rating-on-nkarta-nktx/
Nkarta to Participate in September Investor Conferences
September 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359350/0/en/nkarta-to-participate-in-september-investor-conferences.html
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
November 3 at 1:00 AM  |  Weiss Ratings (Ad)
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357471/0/en/nkarta-to-present-initial-autoimmune-clinical-data-for-nkx019-at-american-college-of-rheumatology-acr-convergence-2026.html
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nkarta-reports-second-quarter-2026-financial-results-and-corporate-highlights-1036438051
Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029
August 10, 2026  |  quiverquant.comQ
See More Nkarta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nkarta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nkarta and other key companies, straight to your email.

About Nkarta

Nkarta (NASDAQ:NKTX) is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors. The company has also worked on manufacturing and cell-engineering technologies intended to support the production of scalable, potentially off-the-shelf cellular therapies.

Founded in 2015 and headquartered in San Francisco, California, Nkarta has conducted development activities through clinical studies and collaborations in the United States. The company is led by President and Chief Executive Officer Paul J. Hastings and continues to focus on advancing its engineered NK-cell platform into potential treatments for serious diseases with significant unmet medical needs.

View Nkarta Profile
Earnings Tools